CIT-013
Rheumatoid Arthritis
About Citryll
Citryll is a clinical-stage biotech developing CIT-013, a first-in-class monoclonal antibody targeting Neutrophil Extracellular Traps (NETs) to treat immune-mediated inflammatory diseases. The company is currently conducting Phase 2a trials in rheumatoid arthritis (RA) and hidradenitis suppurativa (HS), with a pipeline built on a platform targeting citrullinated histones. Founded in 2015 and based in Oss, Netherlands, Citryll is a private, pre-revenue company aiming to establish a new therapeutic class by intervening upstream of current cytokine-targeting therapies.
View full company profileAbout Citryll
Citryll is a clinical-stage biotech developing CIT-013, a first-in-class monoclonal antibody targeting Neutrophil Extracellular Traps (NETs) to treat immune-mediated inflammatory diseases. The company is currently conducting Phase 2a trials in rheumatoid arthritis (RA) and hidradenitis suppurativa (HS), with a pipeline built on a platform targeting citrullinated histones. Founded in 2015 and based in Oss, Netherlands, Citryll is a private, pre-revenue company aiming to establish a new therapeutic class by intervening upstream of current cytokine-targeting therapies.
View full company profileOther Rheumatoid Arthritis Drugs
| Drug | Company | Phase |
|---|---|---|
| Early Detection Test for Rheumatoid Arthritis | Age Labs | Development |
| Piclidenoson (CF101) | Can Fite Biopharma | Phase II/III |
| ERNA-201 | Eterna Therapeutics | Preclinical |
| Tc99m Tilmanocept | Navidea Biopharmaceuticals | Phase 2/3 |
| Monoclonal Antibody Biosimilar (Anti‑TNF) | USV Biologics Division | Phase 1 |
| Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure) | LFB | Pre-clinical |
| EYD-001 (Takinib analog) | EydisBio | Preclinical |
| LFD-200 | Lifordi Immunotherapeutics | Phase 1 |
| MEV-N01 | Mesenbio | Pre-clinical |
| Restem-L | Restem | Phase 2 |
| ASIT Platform | Ahead Therapeutics | Pre-clinical |
| AX-158 | Artax Biopharma | Phase 2 |